Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fresh Tracks Therapeutics, Inc.BBI · Entity 90076 | Chief Business Officer | March 16, 2020 | March 18, 2020 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | CFO and Secretary | February 19, 2026 | February 20, 2026 |
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | Chief Business Officer | February 06, 2019 | February 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fresh Tracks Therapeutics, Inc.
Report date March 16, 2020 · Filed March 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $1.54 · Expires 2030-03-15 | Direct | 20,000 |
Reported balance
After 2020-03-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-16 · Grant · Acquired 20,000 · Balance 20,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.76 · Expires 2029-08-31 | Direct | 111,364 |
Reported balance
Holding disclosure · report date 2020-03-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 111,364 |
Mineralys Therapeutics, Inc.
Report date February 19, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,538 |
Reported balance
After 2026-02-19 transaction · row 1
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 39,900 · Balance 48,538 F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.06 · Expires 2036-02-19 | Direct | 53,300 |
Reported balance
After 2026-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-19 · Grant · Acquired 53,300 · Balance 53,300 F2: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant.
F2: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant
Viridian Therapeutics, Inc.\DE
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2029-02-05 | Direct | 74,000 |
Reported balance
After 2019-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-06 · Grant · Acquired 74,000 · Balance 74,000 F1: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 20, 2026 19:46 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 53,300 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001933414-26-000037 · wk-form4_1771634807.xml · derivative · entry 2 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,300 Underlying: Common Stock · 53,300 shares Expires 2036-02-19 F2 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 19:46 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantCommon Stock | 39,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001933414-26-000037 · wk-form4_1771634807.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,538 F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 20:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,758 | $32.14 | $345,723.39 |
DisclosureSEC source: 0001693134-26-000002 · wk-form4_1768355015.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,638 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.90 to $32.37. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,613 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · derivative · entry 17 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,888 Underlying: Common Stock · 6,613 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of common stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of common stock subject to the option on each monthly anniversary thereafter. F15 · balance_after: Since the date of the Reporting Person's last ownership report, 8,499 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 44,079 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · derivative · entry 16 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,592 Underlying: Common Stock · 44,079 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of common stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of common stock subject to the option on each monthly anniversary thereafter. F14 · balance_after: Since the date of the Reporting Person's last ownership report, 64,329 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 34,414 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · derivative · entry 15 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,662 Underlying: Common Stock · 34,414 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of common stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of common stock subject to the option on each monthly anniversary thereafter. F13 · balance_after: Since the date of the Reporting Person's last ownership report, 42,442 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 20,547 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · derivative · entry 14 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,674 Underlying: Common Stock · 20,547 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. F11 · balance_after: Since the date of the Reporting Person's last ownership report, 13,779 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 32,718 | $46.88 | $1,533,976.89 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 13 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,396 F9 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4900 to $47.3600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 38,900 | $45.93 | $1,786,587.53 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 12 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,114 F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4800 to $46.4725. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 8,456 | $45.18 | $382,046.31 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 11 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,014 F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4700 to $45.4600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 4,142 | $43.50 | $180,183.21 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 10 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,470 F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 8,485 | $42.34 | $359,258.29 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 9 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,612 F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.1000 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 12,952 | $41.65 | $539,479.29 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 8 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,097 F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0550 to $42.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 1,561 | $42.68 | $66,622.54 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 7 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,049 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.5100 to $42.9150. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 11,295 | $41.87 | $472,931.82 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 6 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,610 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.4500 to $42.2800. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 1,015 | $42.00 | $42,630.00 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 5 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,905 Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,613 | $15.44 | $102,104.72 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 4 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 44,079 | $14.25 | $628,125.75 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 3 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 34,414 | $16.00 | $550,624.00 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 2 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 19:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 20,547 | $10.20 | $209,579.40 |
DisclosureSEC source: 0001933414-25-000152 · wk-form4_1763078493.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Since the date of the Reporting Person's last ownership report, 83,598 shares of common stock were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 19:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 3,392 | $42.26 | $143,332.69 |
DisclosureSEC source: 0001933414-25-000130 · wk-form4_1760569476.xml · nonDerivative · entry 2 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,865 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.1600 to $42.3400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 19:04 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 7,366 | $41.90 | $308,650.87 |
DisclosureSEC source: 0001933414-25-000130 · wk-form4_1760569476.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,257 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.1362 to $42.1300. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Since the date of the Reporting Person's last ownership report, 5,311 shares of common stock were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 20:12 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 8,425 | $15.10 | $127,203.18 |
DisclosureSEC source: 0001933414-25-000081 · wk-form4_1753920718.xml · nonDerivative · entry 4 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,934 F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.063 to $15.130. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| July 30, 2025 Filed Jul 30, 2025 20:12 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 51,500 | $14.70 | $757,168.45 |
DisclosureSEC source: 0001933414-25-000081 · wk-form4_1753920718.xml · nonDerivative · entry 3 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,359 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.06 to $15.06. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| July 29, 2025 Filed Jul 30, 2025 20:12 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 807 | $14.00 | $11,301.87 |
DisclosureSEC source: 0001933414-25-000081 · wk-form4_1753920718.xml · nonDerivative · entry 2 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,859 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.01. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:12 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 12,946 | $14.04 | $181,803.27 |
DisclosureSEC source: 0001933414-25-000081 · wk-form4_1753920718.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,666 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.20. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 17:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,758 | $14.45 | $155,454.18 |
DisclosureSEC source: 0001933414-25-000077 · wk-form4_1752613283.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,612 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.3012 to $14.6546. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: This balance includes 2,030 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:36 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,757 | $12.06 | $129,684.24 |
DisclosureSEC source: 0001933414-25-000046 · wk-form4_1744763754.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,340 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.78 to $12.35. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 18:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 170,000 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000020 · wk-form4_1740441586.xml · derivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month anniversary following the date of grant. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:46 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 100 | $9.63 | $963.00 |
DisclosureSEC source: 0001933414-25-000005 · wk-form4_1736995563.xml · nonDerivative · entry 2 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,097 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. Read SEC document |
| January 13, 2025 Filed Jan 15, 2025 21:46 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,657 | $9.09 | $96,900.90 |
DisclosureSEC source: 0001933414-25-000005 · wk-form4_1736995563.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,197 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.60 to $9.52. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 16:22 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,757 | $13.57 | $146,003.69 |
DisclosureSEC source: 0001933414-24-000047 · wk-form4_1729023737.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,854 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.24 to $13.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 16:37 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 10,757 | $13.14 | $141,394.31 |
DisclosureSEC source: 0001933414-24-000034 · wk-form4_1720816673.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,611 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.43. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: This balance includes 2,906 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 17:33 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 96,815 | $12.94 | $1,252,718.33 |
DisclosureSEC source: 0001933414-24-000027 · wk-form4_1718314405.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 255,462 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.79 to $13.29. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: This balance includes 1,466 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 16:26 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001628280-24-005065 · wk-form4_1708032366.xml · derivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 18:47 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001933414-23-000020 · wf-form4_167943885949772.xml · derivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-03-17 F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 16:54 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | PurchaseCommon Stock | 6,250 | $16.00 | $100,000.00 |
DisclosureSEC source: 0001628280-23-003924 · wf-form4_167658446540333.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO, Chief Bus. Off. and Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,811 Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:01 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 97,518 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001628280-23-003424 · wf-form4_167634007134725.xml · derivative · entry 1 Levy Adam Scott · CIK 0001693134 · CFO, Chief Bus. Off. and Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,518 Underlying: Common Stock · 97,518 shares Expires 2033-02-09 F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 16:30 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantRestricted Stock Units · Derivative | 20,000 | $1.54 Strike: $1.54 | $30,800.00 |
DisclosureSEC source: 0001214659-20-002727 · marketforms-48373.xml · derivative · entry 2 Levy Adam Scott · CIK 0001693134 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-03-15 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:32 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 74,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001209191-19-008536 · doc4.xml · derivative · entry 1 Levy Adam Scott · CIK 0001693134 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 17:02 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseCommon Stock | 9,090 | $5.50 | $49,995.00 |
DisclosureSEC source: 0001209191-18-009625 · doc4.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,540 F1 · shares: Represents shares purchased through the Issuer's follow-on public offering. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 20:17 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-18-007267 · doc4.xml · derivative · entry 1 Levy Adam Scott · CIK 0001693134 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-01-30 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on April 30, 2018 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 19:07 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseCommon Stock | 200 | $7.55 | $1,510.00 |
DisclosureSEC source: 0001209191-17-041768 · doc4.xml · nonDerivative · entry 1 Levy Adam Scott · CIK 0001693134 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 20:25 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 87,500 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001209191-17-011779 · doc4.xml · derivative · entry 1 Levy Adam Scott · CIK 0001693134 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2027-02-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in 48 equal monthly installments beginning on February 16, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.